Press Releases

Feb 27, 2017

Veracyte Announces Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis

Read More

Feb 21, 2017

Veracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis

Read More

Feb 15, 2017

Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017

Read More

Feb 08, 2017

Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Through Agreement with Quest Diagnostics

Read More

Feb 06, 2017

Veracyte Announces Final Medicare Coverage Policies for Percepta® Bronchial Genomic Classifier

Read More

Feb 02, 2017

Veracyte to Present at LEERINK Partners 6th Annual Global Healthcare Conference

Read More

Dec 13, 2016

Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors

Read More

Nov 22, 2016

Veracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma® Gene Expression Classifier in 2017

Read More

Nov 21, 2016

Veracyte Appoints Keith Kennedy as Chief Financial Officer

Read More

Nov 15, 2016

Veracyte to Participate in Two Upcoming Investor Conferences

Read More